Kronos Bio Restructures to Extend Cash Runway for Clinical Development

Kronos Bio, Inc., a cancer-focused biopharmaceutical company, has unveiled a restructuring strategy to extend its cash runway into the latter half of 2026. This plan aims to optimize resource allocation towards key projects like the ongoing KB-0742 phase 1/2 study by assessing a new dosing schedule. The company will also continue to develop KB-9558, targeting starting human trials in 2025.

The adjustment involves a 21% workforce reduction to streamline operations. For KB-0742, the company is evaluating a dosing schedule of 80mg four-days-on, three-days-off, promising higher therapeutic levels for patients. Data from this expansion cohort are expected in early 2025. Preliminary data show encouraging anti-tumor activity and a manageable safety profile without severe neutropenia at varying doses.

Alongside these efforts, updated results for KB-0742 will be shared in mid-2024. In December, the drug cleared an 80mg dose using the previous schedule. Kronos Bio plans to include patients with types of cancer such as lung, ovarian, and triple negative breast cancer in the next phase if safety is confirmed.

Additionally, preclinical data for KB-9558 in multiple myeloma will be presented in April 2024. Upon completing studies in 2024, the company targets first-in-human trials for KB-9558 in 2025.

Kronos Bio remains dedicated to advancing treatments for challenging cancers, with ongoing discovery projects and collaborations to support this mission.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!